| Date |
Title |
Rating |
| 2010-03-31 |
Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer |
5 |
| 2010-03-31 |
ViroPharma initiates Phase 2 clinical study to evaluate Cinryze |
None |
| 2010-03-31 |
DSMB for DIGNITY trial recommends Celsion continue enrollment |
None |
| 2010-03-31 |
ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC |
None |
| 2010-03-31 |
Investment report on Sunesis Pharmaceuticals |
None |
| 2010-03-31 |
SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference |
3 |
| 2010-03-31 |
Nymox Pharmaceutical's NX-1207 human clinical trials for HCC demonstrate favorable safety data |
None |
| 2010-03-31 |
PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic |
None |
| 2010-03-31 |
QRxPharma initiates Phase 1 trial for evaluating PK profiles of morphine, oxycodone CR formulations |
None |
| 2010-03-31 |
YM BioSciences receives approval to expand enrolment in Phase I/II clinical trial of CYT387 |
None |
| 2010-03-31 |
Titan Pharmaceuticals commences Phase 3 study of Probuphine for opioid addiction |
None |
| 2010-03-30 |
FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine |
1 |
| 2010-03-30 |
NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss |
None |
| 2010-03-30 |
CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN |
None |
| 2010-03-30 |
Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD |
None |
| 2010-03-30 |
GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer |
None |
| 2010-03-30 |
Trius Therapeutics' Phase 1 trial establishes safety and tolerability of IV torezolid phosphate for MRSA |
None |
| 2010-03-29 |
NexMed files IND with FDA for Phase II trial of PrevOnco for HCC |
None |
| 2010-03-29 |
Interim data comparing Cervista HPV HR to Hybrid Capture 2 presented at 4th Biennial Meeting of AOGIN |
None |
| 2010-03-29 |
Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced |
None |
| 2010-03-29 |
Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress |
4 |
| 2010-03-29 |
Positive results from Pearl Therapeutics' Phase 1 study of inhaled combination bronchodilator for COPD |
None |
| 2010-03-29 |
Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC |
None |
| 2010-03-29 |
Genta reports net loss of $11.7M for fourth-quarter 2009 |
None |
| 2010-03-29 |
ARYx Therapeutics reports net loss of $5.8M for fourth-quarter 2009 |
None |
| 2010-03-26 |
Medtronic announces enrollment of first European patients in randomized controlled trial of ITB Therapy |
None |
| 2010-03-26 |
Avid, Cardinal Health partner to detect Alzheimer's disease in living patients |
None |
| 2010-03-26 |
Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow |
None |
| 2010-03-26 |
NellOne's lead candidate for skeletal muscle wound healing and myocardial infarction demonstrates potential efficacy |
None |
| 2010-03-26 |
Cedars-Sinai investigators to study tadalafil as treatment for progressive muscle disease |
None |
| 2010-03-26 |
Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV |
None |
| 2010-03-26 |
Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule |
None |
| 2010-03-26 |
Interim results from ZALBIN Phase 2B trial in chronic hepatitis C patients announced |
None |
| 2010-03-26 |
FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD |
None |
| 2010-03-26 |
Positive results from Stage A pivotal study of 2009 A/H1N1 VLP pandemic influenza vaccine |
None |
| 2010-03-26 |
Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX |
None |
| 2010-03-26 |
Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C |
None |
| 2010-03-26 |
Independent DMC recommends continuance of enrollment in Eisai's Phase III ACCESS trial |
None |
| 2010-03-26 |
Aastrom Biosciences' RESTORE-CLI trial: Final patient treated |
None |
| 2010-03-26 |
DARA BioSciences announces the initiation of Phase I clinical study for DB959 |
None |
| 2010-03-25 |
Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916 |
None |
| 2010-03-25 |
Scott & White seeks breast cancer patients for Phase II clinical trial |
None |
| 2010-03-25 |
Biogen Idec and Elan begin comparative trial of MS treatments |
5 |
| 2010-03-25 |
Clinic sites seek gay men to participate in HIV vaccine study |
None |
| 2010-03-25 |
Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference |
None |
| 2010-03-24 |
Shingles drug receives clearance for final stage of testing |
None |
| 2010-03-24 |
Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study |
None |
| 2010-03-24 |
CytoDyn provides additional funds for HIV/AIDS drug trial |
None |
| 2010-03-23 |
Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery |
None |
| 2010-03-23 |
Portola Pharmaceuticals commences Phase 1 trial of PRT062607 for chronic inflammatory diseases |
None |
| 2010-03-23 |
Merck Serono, EMD Serono suspend global clinical development program for Stimuvax temporarily |
None |
| 2010-03-23 |
Inhibitex announces net loss of $4.7M for fourth-quarter 2009 |
None |
| 2010-03-23 |
Aradigm reports net loss of $3.4M for fourth-quarter 2009 |
None |
| 2010-03-23 |
Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands |
None |
| 2010-03-23 |
CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval |
None |
| 2010-03-23 |
Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years |
None |
| 2010-03-22 |
Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated |
None |
| 2010-03-22 |
Pevion Biotech commences Phase 1 clinical trial of PEV7 vaccine |
None |
| 2010-03-22 |
ChemoCentryx undertakes Phase II clinical trial of CCX140 |
None |
| 2010-03-22 |
First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat |
None |
| 2010-03-22 |
Simcere Pharmaceutical completes Phase IV clinical study of Endostar |
None |
| 2010-03-22 |
Vical awarded contract to conduct Phase 1 clinical trial of Vaxfectin-formulated DNA vaccine against A/H1N1 |
None |
| 2010-03-22 |
PharmAthene suspends work on SparVax research and development contract with BARDA |
None |
| 2010-03-22 |
Formatech selects Tracon Pharmaceuticals’ TRC102 inhibitor as next Fillanthropy Program candidate |
None |
| 2010-03-22 |
Phase II Topical Interferon Alpha-2b trial for AGW: Helix BioPharma achieves last-patient-out |
None |
| 2010-03-19 |
Major study shoots for personalized breast cancer drugs |
5 |
| 2010-03-19 |
CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement |
None |
| 2010-03-19 |
Synergy Pharmaceuticals commences dosing in Phase IIa clinical trial of SP-304 in CC patients |
None |
| 2010-03-19 |
A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter |
None |
| 2010-03-19 |
Abstract about Phase I/II trial of ThermoDox in RCW accepted for presentation at ASCO 2010 |
None |
| 2010-03-19 |
FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched |
None |
| 2010-03-19 |
Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056 |
None |
| 2010-03-19 |
ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation |
None |
| 2010-03-18 |
Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints |
None |
| 2010-03-18 |
Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series |
None |
| 2010-03-18 |
Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study |
None |
| 2010-03-18 |
Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD |
None |
| 2010-03-18 |
Findings from Study 305 evaluating the effect of Northera reported |
None |
| 2010-03-18 |
Agendia to participate in groundbreaking clinical trial for breast cancer |
None |
| 2010-03-18 |
Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin |
None |
| 2010-03-17 |
Nabi Biopharmaceuticals commences second Phase III study of NicVAX for treating nicotine addiction |
None |
| 2010-03-17 |
ONGLYZA-metformin combination: FDA accepts NDA for review |
2 |
| 2010-03-17 |
Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC |
None |
| 2010-03-17 |
Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002 |
None |
| 2010-03-17 |
Prevenar 13: Immunogenic and well tolerated in young children previously vaccinated with Prevenar |
None |
| 2010-03-17 |
Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD |
None |
| 2010-03-17 |
Abraxis BioScience's Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint |
None |
| 2010-03-17 |
Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications |
None |
| 2010-03-17 |
Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC |
None |
| 2010-03-17 |
TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene |
None |
| 2010-03-17 |
Human Genome Sciences to deploy Aegis Analytical's Discoverant manufacturing intelligence solution |
None |
| 2010-03-17 |
Booster shot appears to improve TB resistance in previously vaccinated adults |
None |
| 2010-03-17 |
Vertex Pharmaceuticals' telaprevir and VX-222 HCV inhibitor abstracts accepted for presentation at 45th EASL meeting |
None |
| 2010-03-16 |
PCI Biotech completes treatment of third dose group in phase I/II study of Amphinex in cancer patients |
None |
| 2010-03-16 |
Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients |
2.5 |
| 2010-03-16 |
Lantheus Medical Imaging announces preliminary data on flurpiridaz F 18 PET MPI agent |
3 |
| 2010-03-16 |
Iverson Genetic Diagnostics to conduct WARFARIN clinical study |
None |
| 2010-03-16 |
Promedior raises $12M in Series C financing |
None |
| 2010-03-16 |
EXPLORE-Xa study: Betrixaban reduces CRNM bleeds compared to dose-adjusted warfarin |
3 |
| 2010-03-16 |
Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint |
None |
| 2010-03-16 |
Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis |
5 |
| 2010-03-16 |
Positive results from Phase IIa epilepsy study of ICA-105665 |
None |
| 2010-03-15 |
Progenics Pharmaceuticals to advance oral methylnaltrexone for OIC into late stage clinical development |
None |
| 2010-03-15 |
CytRx plans five Phase 2 clinical trials with oncology drug candidates |
None |
| 2010-03-15 |
YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR |
None |
| 2010-03-15 |
Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis |
None |
| 2010-03-15 |
Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study |
None |
| 2010-03-15 |
Data from ACCORD Lipid study: Abbott issues statement |
None |
| 2010-03-15 |
Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly |
None |
| 2010-03-15 |
Regadenoson drug is safe for heart transplant patients: Study |
None |
| 2010-03-15 |
XOMA 052 reduces adverse consequences that lead to development of congestive heart failure |
None |
| 2010-03-15 |
ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes |
None |
| 2010-03-12 |
XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients |
5 |
| 2010-03-12 |
TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints |
None |
| 2010-03-12 |
Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009 |
None |
| 2010-03-12 |
CBio recruits 75th patient into XToll phase II clinical trial, achieves milestone under agreement with Novo Nordisk |
None |
| 2010-03-12 |
Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010 |
None |
| 2010-03-12 |
AED Vimpat demonstrates fewer partial-onset seizures in adults with epilepsy |
None |
| 2010-03-12 |
Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints |
None |
| 2010-03-12 |
Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy |
None |
| 2010-03-12 |
Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLC |
None |
| 2010-03-12 |
Neoprobe meets with FDA to review Phase 3 clinical trial results of Lymphoseek drug |
None |
| 2010-03-12 |
Genentech announces topline results from Phase III trial of Avastin |
None |
| 2010-03-12 |
PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS |
None |
| 2010-03-12 |
Baxter International, DVC present Phase III clinical efficacy data for PREFLUCEL |
None |
| 2010-03-11 |
FDA provides guidance on Restanza clinical program in treatment of CABP |
4.7 |
| 2010-03-11 |
Peregrine Pharmaceuticals' third-quarter fiscal 2010 total revenues up 45% |
None |
| 2010-03-11 |
Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study |
None |
| 2010-03-11 |
Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression |
None |
| 2010-03-11 |
Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage |
None |
| 2010-03-11 |
NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil |
4 |
| 2010-03-11 |
Lithera announces positive results from Phase IIa clinical study of LIPO-102 |
None |
| 2010-03-10 |
Positive results from Limerick BioPharma's LIM-0705 Phase 1a trial |
None |
| 2010-03-10 |
NeoPharm seeks Orphan Drug Designation for IL13-PE38QQR in treatment of IPF |
None |
| 2010-03-10 |
Affymax initiates Phase 3 clinical testing of Hematide in Japan, receives $5M milestone payment |
None |
| 2010-03-10 |
Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009 |
None |
| 2010-03-10 |
Cempra Pharmaceuticals completes Phase 1 clinical trials of CEM-101 macrolide |
None |
| 2010-03-10 |
AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B |
None |
| 2010-03-10 |
Helix BioPharma reports 29.9% increase in total revenues for second-quarter fiscal 2010 |
None |
| 2010-03-10 |
Diamyd Medical enrolls over 430 children with newly diagnosed type 1 diabetes in global Phase III program |
None |
| 2010-03-10 |
Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes |
None |
| 2010-03-10 |
Cellectar completes enrollment in (131)I-CLR1404 Phase I dosimetry trial for advanced solid malignancies |
None |
| 2010-03-09 |
Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV |
None |
| 2010-03-09 |
Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury |
None |
| 2010-03-09 |
Phase III study demonstrates superiority of imiquimod cream 2.5% and 3.75% in treatment of AK |
None |
| 2010-03-09 |
JAAD publishes Phase III data evaluating safety and efficacy of imiquimod in patients with AK |
None |
| 2010-03-09 |
Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray |
None |
| 2010-03-08 |
ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC |
None |
| 2010-03-08 |
Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009 |
None |
| 2010-03-08 |
Rexahn Pharmaceuticals granted Japanese patent for Archexin |
None |
| 2010-03-08 |
Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer |
None |
| 2010-03-08 |
NOVAVAX' Stage B 2009 H1N1 VLP pandemic influenza vaccine study in Mexico: Enrollment complete |
None |
| 2010-03-08 |
Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC |
None |
| 2010-03-08 |
VIVUS granted three additional patents for Qnexa |
None |
| 2010-03-08 |
Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals |
None |
| 2010-03-08 |
DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test |
None |
| 2010-03-08 |
Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting |
None |
| 2010-03-06 |
Presentation of results from open-label extension study of Xenazine |
None |
| 2010-03-06 |
Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results |
None |
| 2010-03-05 |
LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting |
None |
| 2010-03-05 |
Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced |
4 |
| 2010-03-05 |
Apixaban superior to enoxaparin in reducing venous thromboembolism in total knee replacement surgery patients |
5 |
| 2010-03-05 |
Data evaluating safety, efficacy of STELARA and REMICADE in patients with plaque psoriasis to be presented |
None |
| 2010-03-04 |
BioVex commences dosing in Phase 1 study of ImmunoVEX live attenuated genital herpes vaccine |
3.2 |
| 2010-03-04 |
Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs |
None |
| 2010-03-04 |
Phase III GOG-212 clinical trial of CTI's OPAXIO for ovarian cancer: Enrollment to continue |
None |
| 2010-03-04 |
Belatacept drug can prevent graft rejection in kidney transplant recipients |
None |
| 2010-03-04 |
Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments |
None |
| 2010-03-04 |
Allergan, Bristol-Myers Squibb sign global exclusive license agreement for EHT/AGN 0001 |
None |
| 2010-03-04 |
Endocyte's PRECEDENT study: DSMB recommends enrollment to continue |
None |
| 2010-03-04 |
Androxal Type C meeting: Repros Therapeutics receives FDA’s version of minutes |
None |
| 2010-03-04 |
Negative results from latrepirdine Phase III clinical trial: Alzheimer's Association disappointed |
None |
| 2010-03-04 |
Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA |
None |
| 2010-03-03 |
Phase 3 trial: Cabazitaxel improves survival in patients with metastatic hormone-refractory prostate cancer |
5 |
| 2010-03-03 |
AGN-209323 small molecule for neuropathic pain: Bristol-Myers Squibb, Allergan announce global agreement |
None |
| 2010-03-03 |
Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients |
None |
| 2010-03-03 |
FDA issues new draft guidance for Trius Therapeutics' proposed Phase 3 trial of torezolid phosphate |
None |
| 2010-03-03 |
Merck’s MF/F Phase III study data presented at AAAAI annual meeting |
None |
| 2010-03-03 |
Merck announces updated late-stage pipeline following its recent merger with Schering-Plough |
5 |
| 2010-03-03 |
Phase III study results of Merck's allergy immunotherapy tablet |
None |
| 2010-03-02 |
Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB |
None |
| 2010-03-02 |
Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development |
None |
| 2010-03-02 |
Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial |
None |
| 2010-03-02 |
Archimedes Pharma raises GBP65 million in new funding |
None |
| 2010-03-02 |
IgPro20 protects PI patients against infection |
None |
| 2010-03-02 |
PTSD drug: Cannabis Science to file first application for FDA clinical trials |
None |
| 2010-03-02 |
Celsion to commence Phase II Study of ThermoDox and RFA for CRLM |
None |
| 2010-03-02 |
Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION |
None |
| 2010-03-01 |
Peer-reviewed articles elucidate role of clusterin in promoting tumor resistance to cancer treatment |
None |
| 2010-03-01 |
Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline |
None |
| 2010-03-01 |
[11C]PiB PET neuroimaging exhibits potential for monitoring therapeutics on amyloid beta load during Alzheimer’s disease treatment |
None |